How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
http://link.springer.com/content/pdf/10.1007/s11912-019-0819-x.pdf
Reference71 articles.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. https://doi.org/10.3322/caac.21551 .
2. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–60. https://doi.org/10.1182/blood-2017-09-806398 .
3. Shanafelt TD, Kay NE, Call TG, Zent CS, Jelinek DF, LaPlant B, et al. MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count >or= 5 x 10(9) L(-1) but a B-cell lymphocyte count <5 x 10(9) L(-1)? Leuk Res. 2008;32(9):1458–61. https://doi.org/10.1016/j.leukres.2007.11.030 .
4. Fung SS, Hillier KL, Leger CS, Sandhu I, Vickars LM, Galbraith PF, et al. Clinical progression and outcome of patients with monoclonal B-cell lymphocytosis. Leuk Lymphoma. 2007;48(6):1087–91. https://doi.org/10.1080/10428190701321277 .
5. Strati P, Shanafelt TD. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood. 2015;126(4):454–62. https://doi.org/10.1182/blood-2015-02-585059 .
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies;Haematologica;2023-09-14
2. Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology;Recent Patents on Anti-Cancer Drug Discovery;2020-12-29
3. Getting the Right Evidence After Drug Approval;Frontiers in Pharmacology;2020-09-09
4. Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia;Biomarker Research;2020-09-07
5. Investigational treatments for chronic lymphocytic leukemia: a focus on phase 1 and 2 clinical trials;Expert Opinion on Investigational Drugs;2020-05-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3